Drug induced oral erythema multiforme: Case report.

Autor:	Asif SM; Department of Diagnostic Science and Oral Biology., Shamsudeen SM; Department of Diagnostic Science and Oral Biology., Assiri KI; Department of Diagnostic Science and Oral Biology., Muburak HMA; Department of Diagnostic Science and Oral Biology., Kaleem SM; Department of Diagnostic Science and Oral Biology., Khan AA; Department of Oral & Maxillofacial Surgery., Shariff M; Department of Prosthetic Dentistry, College of Dentistry, King Khalid University, Abha, Kingdom of Saudi Arabia.
Jazyk:	angličtina
Zdroj:	Medicine [Medicine (Baltimore)] 2021 Apr 30; Vol. 100 (17), pp. e22387.
DOI:	10.1097/MD.0000000000022387
Abstrakt:	Introduction: Drug induced oral erythema multiforme a rare clinical entity which involves only the lips and oral mucosa without skin involvement. These lesions are difficult in diagnosing with other oral ulcerative lesions with similar clinical manifestations. Patient Concerns: This article presents 2 case reports of Oral erythema multiforme in which drugs were the precipitating factor. Its etiopathogenesis, differential diagnosis and treatment modalities of the disease is discussed. Diagnosis: Based on patient's complaints, drug history and clinical appearance, provisional diagnosis of drug induced erythema multiforme was considered. Intervention: For case 1, patient was instructed to discontinue usage of drug and prescribed systemic steroid (Prednisolone 10 mg/d) for a week along with germicidal drugs to prevent secondary infection. Medication was tapered to 5 mg/d after first week.For case 2, patient was instructed to discontinue the drug and systemic steroid prednisolone 20 mg /d for 1 week with tapering dose of 10 mg/d for the second week was administered. Outcome: For case 1 and case 2 healing of the lesions were evident on third week of follow up. Conclusion: Medications should be taken under medical supervision. Over the counter drugs might lead to allergic reactions like drug induced oral erythema multiforme, which is a rare variant and needs to be differentiate from other oral ulcerative lesion for prompt management and follow-up. Competing Interests: The authors have no conflicts of interest to disclose. (Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu